^
    No biomarker
    Gastric Cancer
    nivolumab
    Sensitive: A1 - Approval
    Ono Pharmaceuticals Press Release - 5 days
    HER-2 negative
    Gastric Adenocarcinoma
    cisplatin + paclitaxel + capecitabine
    Sensitive: C3 – Early Trials
    Asia Pac J Clin Oncol - 1 week
    miR-200b underexpression
    Gastric Cancer
    5-fluorouracil
    Resistant: D – Preclinical
    DNA Cell Biol - 2 weeks
    miR-199b overexpression +miR-152 overexpression
    Gastric Cancer
    5-fluorouracil
    Resistant: D – Preclinical
    DNA Cell Biol - 2 weeks
    miR-152 overexpression
    Gastric Cancer
    5-fluorouracil
    Resistant: D – Preclinical
    DNA Cell Biol - 2 weeks
    miR-199b overexpression
    Gastric Cancer
    5-fluorouracil
    Sensitive: D – Preclinical
    DNA Cell Biol - 2 weeks
    miR-103a underexpression
    Gastric Cancer
    5-fluorouracil
    Resistant: D – Preclinical
    DNA Cell Biol - 2 weeks
    miR-200b underexpression + miR-103a underexpression
    Gastric Cancer
    5-fluorouracil
    Resistant: D – Preclinical
    DNA Cell Biol - 2 weeks
    HER-2 positive
    Gastric Cancer
    trastuzumab + ramucirumab + ALX148
    Sensitive: C3 – Early Trials
    SITC 2021 - 3 weeks
    PD-L1 overexpression
    Gastroesophageal Junction Adenocarcinoma
    durvalumab + cabozantinib tablet
    Sensitive: C3 – Early Trials
    SITC 2021 - 3 weeks
    FGFR3 amplification
    Gastric Adenocarcinoma
    pazopanib
    Sensitive: C4 – Case Studies
    Clin Case Rep - 3 weeks
    ICAM1 overexpression
    Gastric Cancer
    AIC100
    Sensitive: D – Preclinical
    SITC 2021 - 3 weeks
    CLDN18.2 positive
    Gastric Cancer
    CLDN18.2-targeted CAR-T immunotherapy
    Sensitive: D – Preclinical
    SITC 2021 - 3 weeks
    HER-2 positive
    Gastroesophageal Junction Adenocarcinoma
    trastuzumab
    Sensitive: A1 - Approval
    No biomarker
    Gastroesophageal Junction Adenocarcinoma
    nivolumab
    Sensitive: A1 - Approval
    No biomarker
    Gastric Adenocarcinoma
    cisplatin + 5-fluorouracil + docetaxel
    Sensitive: A1 - Approval
    No biomarker
    Gastroesophageal Junction Adenocarcinoma
    cisplatin + 5-fluorouracil + docetaxel
    Sensitive: A1 - Approval
    HER-2 positive
    Gastric Cancer
    fam-trastuzumab deruxtecan-nxki
    Sensitive: A1 - Approval
    HER-2 positive
    Gastroesophageal Junction Adenocarcinoma
    fam-trastuzumab deruxtecan-nxki
    Sensitive: A1 - Approval
    No biomarker
    Gastric Cancer
    TPF
    Sensitive: A1 - Approval
    No biomarker
    Gastroesophageal Junction Adenocarcinoma
    TPF
    Sensitive: A1 - Approval
    HER-2 positive
    Gastric Cancer
    pembrolizumab + trastuzumab
    Sensitive: A1 - Approval
    HER-2 negative + PD-L1 expression
    Gastroesophageal Junction Adenocarcinoma
    nivolumab
    Sensitive: A1 - Approval
    HER-2 negative + PD-L1 expression
    Gastroesophageal Junction Adenocarcinoma
    pembrolizumab
    Sensitive: A1 - Approval
    HER-2 negative + PD-L1 expression
    Gastric Cancer
    nivolumab
    Sensitive: A1 - Approval
    HER-2 overexpression
    Gastric Cancer
    trastuzumab
    Sensitive: A1 - Approval
    No biomarker
    Gastroesophageal Junction Adenocarcinoma
    pembrolizumab
    Sensitive: A1 - Approval
    HER-2 positive
    Gastroesophageal Junction Adenocarcinoma
    Trazimera (trastuzumab biosimilar)
    Sensitive: A1 - Approval
    HER-2 overexpression
    Gastric Cancer
    Trazimera (trastuzumab biosimilar)
    Sensitive: A1 - Approval
    HER-2 positive
    Gastroesophageal Junction Adenocarcinoma
    Ontruzant (trastuzumab biosimilar)
    Sensitive: A1 - Approval
    HER-2 overexpression
    Gastric Cancer
    Ontruzant (trastuzumab biosimilar)
    Sensitive: A1 - Approval
    HER-2 positive
    Gastroesophageal Junction Adenocarcinoma
    Ogivri (trastuzumab biosimilar)
    Sensitive: A1 - Approval
    HER-2 overexpression
    Gastric Cancer
    Ogivri (trastuzumab biosimilar)
    Sensitive: A1 - Approval
    HER-2 positive
    Gastroesophageal Junction Adenocarcinoma
    Kanjinti (trastuzumab biosimilar)
    Sensitive: A1 - Approval
    HER-2 overexpression
    Gastric Cancer
    Kanjinti (trastuzumab biosimilar)
    Sensitive: A1 - Approval
    HER-2 positive
    Gastroesophageal Junction Adenocarcinoma
    Herzuma (trastuzumab biosimilar)
    Sensitive: A1 - Approval
    HER-2 overexpression
    Gastric Cancer
    Herzuma (trastuzumab biosimilar)
    Sensitive: A1 - Approval
    No biomarker
    Gastroesophageal Junction Adenocarcinoma
    trifluridine/tipiracil
    Sensitive: A1 - Approval
    No biomarker
    Gastric Cancer
    trifluridine/tipiracil
    Sensitive: A1 - Approval
    No biomarker
    Gastric Cancer
    ramucirumab
    Sensitive: A1 - Approval
    No biomarker
    Gastric Cancer
    capecitabine
    Sensitive: A1 - Approval
    No biomarker
    Gastroesophageal Junction Adenocarcinoma
    ramucirumab
    Sensitive: A1 - Approval
    HER-2 positive
    Gastroesophageal Junction Adenocarcinoma
    Zercepac (trastuzumab biosimilar)
    Sensitive: A1 - Approval
    HER-2 overexpression
    Gastroesophageal Junction Adenocarcinoma
    trastuzumab
    Sensitive: A1 - Approval
    HER-2 overexpression
    Gastric Cancer
    Zercepac (trastuzumab biosimilar)
    Sensitive: A1 - Approval
    HER-2 positive
    Gastric Cancer
    Zercepac (trastuzumab biosimilar)
    Sensitive: A1 - Approval
    HER-2 overexpression
    Gastroesophageal Junction Adenocarcinoma
    Ontruzant (trastuzumab biosimilar)
    Sensitive: A1 - Approval
    HER-2 overexpression
    Gastroesophageal Junction Adenocarcinoma
    Kanjinti (trastuzumab biosimilar)
    Sensitive: A1 - Approval
    HER-2 overexpression
    Gastroesophageal Junction Adenocarcinoma
    Ogivri (trastuzumab biosimilar)
    Sensitive: A1 - Approval
    HER-2 positive
    Gastroesophageal Junction Adenocarcinoma
    pembrolizumab + trastuzumab
    Sensitive: A1 - Approval
    No biomarker
    Gastroesophageal Junction Adenocarcinoma
    disitamab vedotin
    Sensitive: A1 - Approval
    No biomarker
    Gastric Cancer
    disitamab vedotin
    Sensitive: A1 - Approval
    HER-2 positive
    Gastric Cancer
    trastuzumab
    Sensitive: A2 - Guideline
    HER-2 negative
    Gastric Cancer
    cisplatin + capecitabine
    Sensitive: A2 - Guideline
    HER-2 negative
    Gastroesophageal Junction Adenocarcinoma
    cisplatin + capecitabine
    Sensitive: A2 - Guideline
    No biomarker
    Gastroesophageal Junction Adenocarcinoma
    DOF
    Sensitive: A2 - Guideline
    No biomarker
    Gastric Cancer
    TCF
    Sensitive: A2 - Guideline
    No biomarker
    Gastroesophageal Junction Adenocarcinoma
    TCF
    Sensitive: A2 - Guideline
    No biomarker
    Gastroesophageal Junction Adenocarcinoma
    FP
    Sensitive: A2 - Guideline
    No biomarker
    Gastroesophageal Junction Adenocarcinoma
    CaT
    Sensitive: A2 - Guideline
    No biomarker
    Gastric Cancer
    FP
    Sensitive: A2 - Guideline
    No biomarker
    Gastric Cancer
    FOLFIRI
    Sensitive: A2 - Guideline
    HER-2 negative
    Gastroesophageal Junction Adenocarcinoma
    CAPOX
    Sensitive: A2 - Guideline
    HER-2 negative
    Gastroesophageal Junction Adenocarcinoma
    5-fluorouracil + oxaliplatin
    Sensitive: A2 - Guideline
    HER-2 negative
    Gastroesophageal Junction Adenocarcinoma
    FP
    Sensitive: A2 - Guideline
    No biomarker
    Gastroesophageal Junction Adenocarcinoma
    capecitabine
    Sensitive: A2 - Guideline
    No biomarker
    Gastroesophageal Junction Adenocarcinoma
    5-fluorouracil
    Sensitive: A2 - Guideline
    No biomarker
    Gastroesophageal Junction Adenocarcinoma
    DP
    Sensitive: A2 - Guideline
    No biomarker
    Gastric Cancer
    5-fluorouracil
    Sensitive: A2 - Guideline
    No biomarker
    Gastric Cancer
    5-fluorouracil + irinotecan
    Sensitive: A2 - Guideline
    HER-2 negative
    Gastric Cancer
    cisplatin + 5-fluorouracil
    Sensitive: A2 - Guideline
    HER-2 negative
    Gastric Cancer
    CAPOX
    Sensitive: A2 - Guideline
    HER-2 negative
    Gastric Cancer
    5-fluorouracil + oxaliplatin
    Sensitive: A2 - Guideline
    No biomarker
    Gastric Cancer
    paclitaxel + 5-fluorouracil
    Sensitive: A2 - Guideline
    No biomarker
    Gastric Cancer
    paclitaxel + capecitabine
    Sensitive: A2 - Guideline
    TMB-H
    Gastric Cancer
    pembrolizumab
    Sensitive: A2 - Guideline
    No biomarker
    Gastric Cancer
    FLOT
    Sensitive: A2 - Guideline
    No biomarker
    Gastroesophageal Junction Adenocarcinoma
    FLOT
    Sensitive: A2 - Guideline
    HER-2 positive
    GastroEsophageal Cancer
    trastuzumab
    Sensitive: A2 - Guideline
    PD-L1 expression
    Gastric Adenocarcinoma
    pembrolizumab
    Sensitive: A2 - Guideline
    No biomarker
    Gastric Cancer
    cisplatin + irinotecan
    Sensitive: A2 - Guideline
    No biomarker
    Gastric Cancer
    irinotecan
    Sensitive: A2 - Guideline
    No biomarker
    Gastric Cancer
    paclitaxel
    Sensitive: A2 - Guideline
    No biomarker
    Gastric Cancer
    docetaxel
    Sensitive: A2 - Guideline
    No biomarker
    Gastric Cancer
    docetaxel + irinotecan
    Sensitive: A2 - Guideline
    No biomarker
    Gastric Cancer
    cisplatin + docetaxel
    Sensitive: A2 - Guideline
    No biomarker
    Gastric Cancer
    carboplatin + paclitaxel
    Sensitive: A2 - Guideline
    No biomarker
    Gastric Cancer
    CAPOX
    Sensitive: A2 - Guideline
    No biomarker
    Gastric Cancer
    5-fluorouracil + oxaliplatin
    Sensitive: A2 - Guideline
    MSI-H/dMMR
    Gastroesophageal Junction Adenocarcinoma
    pembrolizumab
    Sensitive: A2 - Guideline
    No biomarker
    Gastroesophageal Junction Adenocarcinoma
    cisplatin + capecitabine
    Sensitive: A2 - Guideline
    No biomarker
    Gastroesophageal Junction Adenocarcinoma
    5-fluorouracil + irinotecan
    Sensitive: A2 - Guideline
    No biomarker
    Gastroesophageal Junction Adenocarcinoma
    irinotecan
    Sensitive: A2 - Guideline
    No biomarker
    Gastroesophageal Junction Adenocarcinoma
    paclitaxel
    Sensitive: A2 - Guideline
    No biomarker
    Gastroesophageal Junction Adenocarcinoma
    docetaxel
    Sensitive: A2 - Guideline
    No biomarker
    Gastroesophageal Junction Adenocarcinoma
    docetaxel + irinotecan
    Sensitive: A2 - Guideline
    No biomarker
    Gastroesophageal Junction Adenocarcinoma
    IP
    Sensitive: A2 - Guideline
    No biomarker
    Gastroesophageal Junction Adenocarcinoma
    5-fluorouracil + oxaliplatin
    Sensitive: A2 - Guideline
    No biomarker
    Gastroesophageal Junction Adenocarcinoma
    capecitabine + oxaliplatin
    Sensitive: A2 - Guideline
    NTRK3 fusion
    Gastroesophageal Junction Adenocarcinoma
    larotrectinib
    Sensitive: A2 - Guideline
    NTRK2 fusion
    Gastroesophageal Junction Adenocarcinoma
    larotrectinib
    Sensitive: A2 - Guideline
    NTRK1 fusion
    Gastroesophageal Junction Adenocarcinoma
    larotrectinib
    Sensitive: A2 - Guideline
    NTRK3 fusion
    Gastroesophageal Junction Adenocarcinoma
    entrectinib
    Sensitive: A2 - Guideline
    NTRK2 fusion
    Gastroesophageal Junction Adenocarcinoma
    entrectinib
    Sensitive: A2 - Guideline
    NTRK1 fusion
    Gastroesophageal Junction Adenocarcinoma
    entrectinib
    Sensitive: A2 - Guideline